MEIRAGTX HOLDINGS PLC (MGTX) Stock Overview
USA - NASDAQ:MGTX - KYG596651029 - Common Stock
MGTX Key Statistics, Chart & Performance
The current stock price of MGTX is 8.18 USD. In the past month the price increased by 9.21%. In the past year, price increased by 92.02%.
MGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 389.72B | ||
| AMGN | AMGEN INC | 12.52 | 146.96B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.77 | 98.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.51B | ||
| ARGX | ARGENX SE - ADR | 76.77 | 43.55B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.71 | 38.76B | ||
| INSM | INSMED INC | N/A | 28.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.37B | ||
| BIIB | BIOGEN INC | 8.58 | 20.14B |
Related stock screener links
About MGTX
Company Profile
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 386 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Company Info
MEIRAGTX HOLDINGS PLC
450 East 29Th Street, 14Th Floor
New York City NEW YORK 10016 US
CEO: Alexandria Forbes
Employees: 386
Phone: 16468607985
MEIRAGTX HOLDINGS PLC / MGTX FAQ
What is the stock price of MEIRAGTX HOLDINGS PLC today?
The current stock price of MGTX is 8.18 USD. The price decreased by -0.12% in the last trading session.
What is the ticker symbol for MEIRAGTX HOLDINGS PLC stock?
The exchange symbol of MEIRAGTX HOLDINGS PLC is MGTX and it is listed on the Nasdaq exchange.
On which exchange is MGTX stock listed?
MGTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MEIRAGTX HOLDINGS PLC stock?
12 analysts have analysed MGTX and the average price target is 27.88 USD. This implies a price increase of 240.83% is expected in the next year compared to the current price of 8.18. Check the MEIRAGTX HOLDINGS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEIRAGTX HOLDINGS PLC worth?
MEIRAGTX HOLDINGS PLC (MGTX) has a market capitalization of 658.08M USD. This makes MGTX a Small Cap stock.
How many employees does MEIRAGTX HOLDINGS PLC have?
MEIRAGTX HOLDINGS PLC (MGTX) currently has 386 employees.
What are the support and resistance levels for MEIRAGTX HOLDINGS PLC (MGTX) stock?
MEIRAGTX HOLDINGS PLC (MGTX) has a support level at 7.68 and a resistance level at 8.9. Check the full technical report for a detailed analysis of MGTX support and resistance levels.
Is MEIRAGTX HOLDINGS PLC (MGTX) expected to grow?
The Revenue of MEIRAGTX HOLDINGS PLC (MGTX) is expected to grow by 496.23% in the next year. Check the estimates tab for more information on the MGTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEIRAGTX HOLDINGS PLC (MGTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MGTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MGTX, evaluating the profitability, health, valuation and growth aspects
- MEIRAGTX HOLDINGS PLC (MGTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEIRAGTX HOLDINGS PLC (MGTX) Sales and EPS estimates to see what analysts future expectations are.
- MEIRAGTX HOLDINGS PLC (MGTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEIRAGTX HOLDINGS PLC (MGTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEIRAGTX HOLDINGS PLC (MGTX) Stock Chart to make your own analysis
- MEIRAGTX HOLDINGS PLC (MGTX) Latest news and press-releases to stay up to date.
Does MEIRAGTX HOLDINGS PLC (MGTX) stock pay dividends?
MGTX does not pay a dividend.
When does MEIRAGTX HOLDINGS PLC (MGTX) report earnings?
MEIRAGTX HOLDINGS PLC (MGTX) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of MEIRAGTX HOLDINGS PLC (MGTX)?
MEIRAGTX HOLDINGS PLC (MGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
What is the Short Interest ratio of MEIRAGTX HOLDINGS PLC (MGTX) stock?
The outstanding short interest for MEIRAGTX HOLDINGS PLC (MGTX) is 7.26% of its float. Check the ownership tab for more information on the MGTX short interest.
MGTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MGTX. When comparing the yearly performance of all stocks, MGTX is one of the better performing stocks in the market, outperforming 92.59% of all stocks.
MGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MGTX. MGTX has a bad profitability rating. Also its financial health evaluation is rather negative.
MGTX Financial Highlights
Over the last trailing twelve months MGTX reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 8.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.26% | ||
| ROE | -5321.11% | ||
| Debt/Equity | 24.92 |
MGTX Forecast & Estimates
12 analysts have analysed MGTX and the average price target is 27.88 USD. This implies a price increase of 240.83% is expected in the next year compared to the current price of 8.18.
For the next year, analysts expect an EPS growth of 13.44% and a revenue growth 496.23% for MGTX